Spots Global Cancer Trial Database for CT-2106 for the Second Line Treatment of Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CT-2106 for the Second Line Treatment of Ovarian Cancer
Official Title: Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen
Study ID: NCT00291837
Conditions
Interventions
Study Description
Brief Summary: The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Lyon, , France
, Saint Brieuc, , France
, Campobasso, , Italy
, Birmingham, , United Kingdom
, London, , United Kingdom
, Newcastle upon Tyne, , United Kingdom
, Surrey, , United Kingdom
Contact Details
Name: Hilary Calvert, PhD
Affiliation: Newcastle General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
